We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




New Imaging Agent to Drive Step-Change for Brain Cancer Imaging

By MedImaging International staff writers
Posted on 07 Nov 2024
Print article
Image: The Pixclara PET imaging agent for glioma could provide patients with greater diagnostic clarity (Photo courtesy of Telix)
Image: The Pixclara PET imaging agent for glioma could provide patients with greater diagnostic clarity (Photo courtesy of Telix)

Gliomas are highly diffusely infiltrative tumors that impact the surrounding brain tissue. They represent the most prevalent type of central nervous system (CNS) neoplasm originating from glial cells, accounting for around 30% of all brain and CNS tumors and approximately 80% of malignant brain tumors. There is a significant unmet need to enhance the diagnosis and management of gliomas, particularly after treatment. Traditional MRI imaging techniques have various limitations, such as a lack of biological specificity, reliance on the disruption of the blood-brain barrier, and an intrinsic inability to distinguish between tumor progression and treatment-related changes. These issues can lead to inconclusive results, delaying critical treatment decisions. With low survival rates and the necessity for prompt actions, precision imaging becomes essential. Now, a new PET imaging agent for gliomas has the potential to meet this need, providing patients with clearer diagnoses and aiding treatment decision-making.

Telix Pharmaceuticals (Melbourne, Australia) has developed Pixclara (18F-floretyrosine or 18F-FET), a PET agent designed to differentiate between progressive or recurrent gliomas and treatment-related changes in both adult and pediatric patients. The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara), an imaging agent for gliomas. This application has been given priority review status, with a Prescription Drug User Fee Act (PDUFA) goal date set for April 26, 2025, facilitating a potential U.S. commercial launch in 2025.

While FET PET is already part of international clinical practice guidelines for glioma imaging, there is currently no FDA-approved targeted amino acid PET agent available for adult and pediatric brain cancer imaging in the U.S. Given its potential to fulfill a significant medical need, Pixclara has been designated as an orphan drug and granted fast track designation by the FDA. Telix is also exploring the possibility of using Pixclara as a companion diagnostic agent for TLX101-Tx, an investigational neuro-oncology drug in development that targets the same amino acid transporter mechanism with therapeutic radiation.

“Telix believes that the FDA approval of Pixclara will drive a step-change for brain cancer imaging in the U.S., and bring it into line with a more advanced standard of care currently used in other markets,” said Kevin Richardson, Chief Executive Officer, Telix Precision Medicine. “There is currently a critical need for better imaging in brain cancer, and Telix is dedicated to delivering precision medicine solutions that address patient needs and enhance both cancer imaging and treatment outcomes.”

Related Links:
Telix Pharmaceuticals

New
Gold Member
X-Ray QA Meter
T3 AD Pro
Portable Color Doppler Ultrasound Scanner
DCU10
New
Gold Member
X-Ray QA Meter
T3 RG Pro
New
Digital Radiographic System
OMNERA 300M

Print article

Channels

MRI

view channel
Image: A molecular trap for exotic metals promises improved diagnostics and faster drug development (Photo courtesy of Tomáš Belloň/IOCB Prague)

New Compounds to Benefit Kidney Disease Patients Unable to Undergo MRI Examinations

Lanthanides play a vital role in biomedical fields, including as contrast agents for magnetic resonance imaging (MRI) and in radiotherapeutics. However, enhancing their binding strength within pharmaceutical... Read more

General/Advanced Imaging

view channel
Image: Transaxial image of a lung cancer screening CT scan showing coronary artery calcium in all three coronary arteries (Photo courtesy of CMAJ DOI/10.1503/cmaj.231602)

Lung Scans Detect Heart Disease in Patients Without Cardiac Symptoms

Low-dose chest computed tomography (CT) is a standard method used for lung cancer screening. Now, new research has shown that these CT scans can also detect coronary artery calcium, a significant risk... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.